MOTS-c vs SLU-PP-332 vs 5-Amino-1MQ: Mechanism, Evidence, Cost, and Which One Fits

MOTS-c is a 16-amino-acid peptide, and the unusual thing about it is where its gene sits. Almost every peptide in the body is encoded in the DNA of the cell nucleus. MOTS-c is encoded in the mitochondrial genome, inside a short open reading frame in the gene for the 12S ribosomal RNA, which is where the name comes from: "mitochondrial open reading frame of the 12S rRNA-c." It was identified in a 2015 paper in Cell Metabolism from a group at the University of Southern California. It is not a growth hormone secretagogue, not a GLP-1 medication and not a stimulant. The full reference is at what is MOTS-c.

• The folate cycle and AMPK. The original 2015 Cell Metabolism paper reported that, in cultured cells, MOTS-c inhibits the folate cycle, causing a molecule called AICAR to build up. AICAR activates AMPK, the low-fuel sensor that exercise and calorie restriction also switch on. Skeletal muscle appeared to be the main target.
• A messenger to the nucleus. A 2018 Cell Metabolism paper reported that under glucose restriction MOTS-c moves into the nucleus and changes which nuclear genes are switched on. This is cell work.
• The exercise connection. A 2021 paper in Nature Communications reported better physical performance in treated mice at every age tested, and that in humans a bout of exercise raised the body's own MOTS-c in muscle and blood. That human finding is observational, and it is the source of the "exercise-mimetic" label.

There are no randomised controlled trials of MOTS-c in humans. The human data is observational work on the body's own MOTS-c, such as a 2019 Qatar study in Frontiers in Endocrinology reporting lower levels in people with type 2 diabetes. A modified analogue, CB4211, went through a small company-run Phase 1 program reported in 2021, but it is a different molecule and the results were never peer-reviewed.

SLU-PP-332 is not a peptide. It is a small synthetic organic molecule built around a naphthalene ring and a phenol, designed to bind the estrogen-related receptors ERRα, ERRβ and ERRγ. Despite the name, those receptors do not bind estrogen; they sit on DNA and control the genes that build mitochondria and oxidise fatty acids. SLU stands for Saint Louis University, where it came out of the pharmacology group of Thomas Burris, published in ACS Chemical Biology in 2023. The full reference is at what is SLU-PP-332.

• ERR activation and mitochondrial genes. It binds all three ERR subtypes, most potently ERRα, and the 2023 paper reported increased mitochondrial function and respiration in a mouse muscle cell line.
• The acute aerobic-exercise gene program. A single dose in mice induced a gene set strikingly similar to a bout of endurance exercise, and mice engineered to lack ERRα did not show it. That knockout test is a higher standard than most compounds in this category meet.
• More oxidative muscle fibres. Treated mice had a higher proportion of type IIa oxidative fibres and ran further and for longer on a treadmill.
• Whole-body energy expenditure. A 2024 paper in the Journal of Pharmacology and Experimental Therapeutics reported higher energy expenditure and fatty acid oxidation, with less fat mass gained, in two mouse models of obesity.

None in people. There are no published human trials of any phase and no human pharmacokinetic data. The nearest thing is a 2025 pilot study in Frontiers in Physiology in which muscle cells taken from inactive women during hip surgery were treated in a dish.

5-Amino-1MQ is short for 5-amino-1-methylquinolinium. It is a small synthetic molecule, not a peptide: there is no chain of amino acids in it. It came from a medicinal chemistry program at the University of Texas Medical Branch in Galveston, which screened compounds against the enzyme nicotinamide N-methyltransferase (NNMT) in a 2017 Journal of Medicinal Chemistry paper. The reason anyone looked was a 2014 paper in Nature reporting that knocking NNMT down protected mice against diet-induced obesity. The full reference is at what is 5-Amino-1MQ.

• Blocking NNMT. NNMT takes nicotinamide, a form of vitamin B3 the cell recycles into NAD+, and attaches a methyl group from SAM, so the product is excreted rather than reused. Blocking it is proposed to keep both NAD+ precursor and SAM in the cell.
• NAD+ and SAM in cultured fat cells. A 2018 paper in Biochemical Pharmacology reported higher intracellular NAD+ and SAM and less fat-building inside cultured adipocytes. This is the origin of the "raises NAD+" description, and it is a cell-culture result.
• Weight and fat in obese mice. The same 2018 work reported lower body weight and white fat mass in diet-induced obese mice with food intake unchanged. A 2024 paper in Diabetes, Obesity and Metabolism dosed it once daily for 28 days and reported limited fat gain and improved glucose tolerance in obese mice.

None. There are no human trials of any design, and as of September 2026 none registered under its name. The human data is about the target, not the drug: a 2015 Diabetologia study reported roughly twofold higher NNMT expression in the fat tissue of people with type 2 diabetes.

MOTS-c tends to suit someone who wants a peptide rather than a synthetic drug-like compound, who is training, and who is interested in the muscle and insulin-sensitivity side of metabolism. It has the broadest animal literature of the three, the only human data on the natural molecule, and it is the one that has been through an FDA advisory committee. It also comes as a pre-filled pepti Pen.

SLU-PP-332 is the one built most directly around endurance. It suits someone training seriously who is not a tested athlete and who understands that the evidence is entirely in mice and cells. The researchers who made it describe it as a candidate for people who cannot exercise adequately, not a replacement for training in people who can.

5-Amino-1MQ is the fat-cell option. It suits someone whose interest is fat metabolism or the NAD+ angle, with diet and activity already in place. Both of its main mouse studies paired it with a lifestyle change and reported the combination doing more than either alone.

They act on different targets, and some physicians do combine them. The FUSION Blend puts MOTS-c and 5-Amino-1MQ in one vial with BPC-157 and tesamorelin. No study has tested any combination of the three, so stacking them means several unknowns at once rather than one. Most people start with one and add another only if there is a reason to.